Acetazolamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
ACETAZOLAMIDE: Drug Repurposing Evaluation Report
One-Sentence Summary
Acetazolamide (DrugBank: DB00819) is a well-known carbonic anhydrase inhibitor historically used for glaucoma, epilepsy, altitude sickness, and edema. The TxGNN model has not generated any predicted new indications for this drug at present. Combined with the absence of Taiwan market authorization and significant data gaps, this candidate is currently on hold pending further data collection.
Quick Overview
| Item | Content |
|---|---|
| Drug Name (INN) | ACETAZOLAMIDE |
| DrugBank ID | DB00819 |
| Original Indication | Not available in current dataset |
| Predicted New Indication | None (no TxGNN predictions generated) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — No predictions or supporting studies available |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on widely known pharmacological information, Acetazolamide is a carbonic anhydrase inhibitor (sulfonamide derivative) that reduces the formation of hydrogen and bicarbonate ions, leading to decreased fluid secretion. It has established clinical use globally for conditions including glaucoma (reducing intraocular pressure), epilepsy (adjunctive therapy), altitude sickness prophylaxis, and edema associated with heart failure.
However, the TxGNN model has not generated any predicted new indications for Acetazolamide in the current analysis run. This may be due to incomplete input data, the drug's absence from the Taiwan regulatory database, or the model determining that no novel indication reached the confidence threshold. Without a predicted indication, no mechanism-to-disease bridging analysis can be performed at this time.
The primary data gaps — missing MOA data in the evidence pack and missing TFDA package insert warnings — are classified as High and Blocking severity respectively, which further limits the ability to conduct a meaningful repurposing evaluation.
Clinical Trial Evidence
Currently no predicted indication has been generated by TxGNN; therefore, no targeted clinical trial search was conducted.
Literature Evidence
Currently no predicted indication has been generated by TxGNN; therefore, no targeted literature search was conducted.
Taiwan Market Information
Acetazolamide is currently not marketed in Taiwan. No TFDA authorization records were found (0 licenses).
Safety Considerations
Please refer to the package insert for safety information. Current evidence pack contains no TFDA package insert warnings, contraindications, or drug-drug interaction data for this drug in Taiwan. This is flagged as a Blocking data gap (DG001) that must be resolved before proceeding to Stage 1 safety assessment.
Data Gaps Summary
The following critical data gaps were identified and must be addressed:
| Gap ID | Item | Severity | Impact | Remediation |
|---|---|---|---|---|
| DG001 | TFDA Package Insert Warnings/Contraindications | Blocking | Cannot enter S1 safety preliminary assessment | Download and parse package insert PDF from TFDA website |
| DG002 | Mechanism of Action (MOA) | High | Affects mechanism-relevance analysis | Query DrugBank API |
Conclusion and Next Steps
Decision: Hold
Rationale: No TxGNN-predicted indications were generated for Acetazolamide, and there are blocking-level data gaps in safety information. Without a candidate new indication and baseline safety data, advancing this drug through the repurposing pipeline is not warranted at this time.
To proceed, the following is needed:
- Resolve DG001 (Blocking): Obtain TFDA package insert data — download and parse the official package insert PDF to populate warnings and contraindications
- Resolve DG002 (High): Retrieve detailed MOA data from DrugBank API to enable mechanism-based analysis
- Re-run the TxGNN prediction model with complete input data (MOA, indication, safety profile) to determine if any new indications reach the confidence threshold
- Investigate whether Acetazolamide's absence from the Taiwan market (未上市) affects its eligibility for the repurposing pipeline, or whether international registration data can be used as a substitute
- If TxGNN predictions are generated after data gap resolution, update this report with clinical trial and literature evidence
| *Report generated: 2026-04-03 | Evidence Pack version: v4 | Candidate ID: TW-DB00819-multi* |
Disclaimer: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.